Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,338 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Resolution Clear all
Completed Phase 2 Interventional Results available

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

NCT03216902
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 23, 2026, 12:18 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT02275481
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Arformoterol tartrate inhalation solution, Tiotropium
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Waterbury, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Not applicable Interventional

Mobile Health Monitoring Solution for Heart Failure Patients

NCT02594007
View directory record Official record
Conditions
Heart Failure
Interventions
SEEQ, Cardiocom, DocView
Device
Lead sponsor
Atlantic Health System
Other
Eligibility
55 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Jul 23, 2026, 12:18 PM EDT
Recruiting Phase 3 Interventional

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

NCT05401357
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
9
States / cities
Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Jul 23, 2026, 12:18 PM EDT
Terminated Phase 2 Interventional Results available

High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy

NCT04461509
View directory record Official record
Conditions
Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Genital Diseases, Male, Prostatic Disease
Interventions
18F-PSMA
Drug
Lead sponsor
Alessandro D'Agnolo
Other
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 12:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone

NCT05519007
View directory record Official record
Conditions
Joint Infection
Interventions
No-Rinse Solution (NS), Saline irrigation
Other
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
936 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
Manhasset, New York • New Hyde Park, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

NCT02406287
View directory record Official record
Conditions
Healthy Subjects
Interventions
Netarsudil (AR-13324) Ophthalmic Solution, Netarsudil (AR-13324) Ophthalmic Solution Placebo
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Jul 23, 2026, 12:18 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome

NCT03458416
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

NCT03837743
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DUR-928 Topical Solution, Vehicle Topical Solution
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 2 Interventional

A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

NCT03207906
View directory record Official record
Conditions
Chemotherapy-Associated Paronychia
Interventions
VBP-926
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Fountain Valley, California • Chicago, Illinois • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 23, 2026, 12:18 PM EDT
Not listed Not applicable Interventional

Assessment of Heart Failure (HF) At-Home Management Solution ADI Cardio Pulmonary Monitoring System (CPM)

NCT05980585
View directory record Official record
Conditions
Heart Failure
Interventions
CPM Device
Device
Lead sponsor
Analog Device, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 4 Interventional Results available

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

NCT01376804
View directory record Official record
Conditions
Kidney Transplantation, Cytomegalovirus Infections
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
4 Months to 16 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Gainesville, Florida • Los Angeles, Louisiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 2 Interventional Results available

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

NCT02796651
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease - COPD
Interventions
Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Placebo for formoterol fumarate, Formoterol fumarate (12 μg), Formoterol fumarate (40 μg)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jul 23, 2026, 12:18 PM EDT
Recruiting Not applicable Interventional

High Resolution Gastric Mapping and Gastroduodenal Manometry

NCT06941545
View directory record Official record
Conditions
Dyspepsia
Interventions
Alimetry, tVNS, Gastroduodenal Manometry
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 23, 2026, 12:18 PM EDT
Recruiting Not applicable Interventional

The ArtixASCEND Study

NCT07135895
View directory record Official record
Conditions
Acute Lower Limb Arterial Occlusion
Interventions
Artix Thrombectomy System
Device
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Pensacola, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

NCT02034591
View directory record Official record
Conditions
Healthy Subjects
Interventions
Apixaban, Boost Plus
Drug · Dietary Supplement
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 2 Interventional

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)

NCT00680160
View directory record Official record
Conditions
Onychomycosis
Interventions
AN2690
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Jul 23, 2026, 12:18 PM EDT
Withdrawn Not applicable Interventional

Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma

NCT01489410
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Drug-Eluting Beads (DEB) with Doxorubicin, Lipiodol Ethanol Mixture
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Jul 23, 2026, 12:18 PM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT04252586
View directory record Official record
Conditions
Rett Syndrome, RTT
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Jul 23, 2026, 12:18 PM EDT
Not listed Phase 3 Interventional

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

NCT03051490
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase, porcine PERT
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 3 Interventional Results available

A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease

NCT05403827
View directory record Official record
Conditions
Dry Eye Disease
Interventions
K-161, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 23, 2026, 12:18 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Oral Rehydration Solution and Dehydration Recovery

NCT06368765
View directory record Official record
Conditions
Dehydration
Interventions
Oral Rehydration Solution (ORS), Water
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jul 23, 2026, 12:18 PM EDT
Completed Phase 4 Interventional

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936
View directory record Official record
Conditions
Cataract Surgery
Interventions
Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension, Prednisolone Acetate 1%
Drug
Lead sponsor
Silverstein Eye Centers
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 23, 2026, 12:18 PM EDT